NO20032946D0 - Inhalasjonspreparat av aztreonam for behandling og forebyggelse av pulmonale bakterieinfeksjoner - Google Patents

Inhalasjonspreparat av aztreonam for behandling og forebyggelse av pulmonale bakterieinfeksjoner

Info

Publication number: NO20032946D0
Authority: NO; Norway
Prior art keywords: treatment; aztreonam; bacterial infections; formulation; prevention
Prior art date: 2000-12-27

Application number

NO20032946A

Other languages

English (en)

Other versions

NO329643B1 (no

NO20032946L (no

Inventor

Alan Bruce Montgomery

Original Assignee

Salus Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-27

Filing date

2003-06-26

Publication date

2003-06-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980480&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032946(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-06-26 Application filed by Salus Pharma Inc filed Critical Salus Pharma Inc

2003-06-26 Publication of NO20032946D0 publication Critical patent/NO20032946D0/no

2003-08-26 Publication of NO20032946L publication Critical patent/NO20032946L/no

2010-11-22 Publication of NO329643B1 publication Critical patent/NO329643B1/no

Links

WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 title abstract 3
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 title abstract 3
229960003644 aztreonam Drugs 0.000 title abstract 3
208000035143 Bacterial infection Diseases 0.000 title abstract 2
208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
230000002685 pulmonary effect Effects 0.000 title abstract 2
230000002265 prevention Effects 0.000 title 1
239000000203 mixture Substances 0.000 abstract 4
238000009472 formulation Methods 0.000 abstract 3
241000589517 Pseudomonas aeruginosa Species 0.000 abstract 2
241001673062 Achromobacter xylosoxidans Species 0.000 abstract 1
239000004475 Arginine Substances 0.000 abstract 1
241000894006 Bacteria Species 0.000 abstract 1
241000589513 Burkholderia cepacia Species 0.000 abstract 1
241000588914 Enterobacter Species 0.000 abstract 1
241000588724 Escherichia coli Species 0.000 abstract 1
241000606768 Haemophilus influenzae Species 0.000 abstract 1
241000588749 Klebsiella oxytoca Species 0.000 abstract 1
241000588747 Klebsiella pneumoniae Species 0.000 abstract 1
241000588770 Proteus mirabilis Species 0.000 abstract 1
101000794822 Serratia marcescens Anthranilate synthase component 1 Proteins 0.000 abstract 1
101000847781 Serratia marcescens Anthranilate synthase component 2 Proteins 0.000 abstract 1
241000122973 Stenotrophomonas maltophilia Species 0.000 abstract 1
239000000443 aerosol Substances 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
150000001483 arginine derivatives Chemical class 0.000 abstract 1
229940047650 haemophilus influenzae Drugs 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Materials For Medical Uses (AREA)

NO20032946A 2000-12-27 2003-06-26 Aztreonamblanding og anvendelse derav NO329643B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25842300P	2000-12-27	2000-12-27
PCT/US2001/050062 WO2002051356A2 (en)	2000-12-27	2001-12-20	Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (3)

Publication Number	Publication Date
NO20032946D0 true NO20032946D0 (no)	2003-06-26
NO20032946L NO20032946L (no)	2003-08-26
NO329643B1 NO329643B1 (no)	2010-11-22

Family

ID=22980480

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20032946A NO329643B1 (no)	2000-12-27	2003-06-26	Aztreonamblanding og anvendelse derav
NO20101377A NO20101377L (no)	2000-12-27	2010-10-05	Aztreonamblanding og anvendelse derav
NO2011001C NO2011001I2 (no)	2000-12-27	2011-01-25	Aztreonam eller et farmasøytisk akseptabelt salt derav som ikke er et argininsalt

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20101377A NO20101377L (no)	2000-12-27	2010-10-05	Aztreonamblanding og anvendelse derav
NO2011001C NO2011001I2 (no)	2000-12-27	2011-01-25	Aztreonam eller et farmasøytisk akseptabelt salt derav som ikke er et argininsalt

Country Status (19)

Country	Link
US (6)	US6660249B2 (no)
EP (2)	EP1353647B1 (no)
JP (1)	JP4646489B2 (no)
AT (1)	ATE502623T1 (no)
AU (1)	AU2002231244B2 (no)
BE (1)	BE2011C029I2 (no)
BR (1)	BRPI0116757B8 (no)
CA (2)	CA2433280C (no)
CY (2)	CY1111571T1 (no)
DE (2)	DE122011100043I1 (no)
DK (2)	DK1353647T3 (no)
ES (2)	ES2406405T3 (no)
FR (1)	FR11C0030I2 (no)
IL (3)	IL156596A0 (no)
LU (1)	LU91851I2 (no)
NL (1)	NL300492I2 (no)
NO (3)	NO329643B1 (no)
PT (2)	PT2301524E (no)
WO (1)	WO2002051356A2 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7214364B2 (en) *	2000-12-27	2007-05-08	Corus Pharma, Inc.	Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) *	2000-12-27	2006-11-21	Corus Pharma, Inc.	Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
IL156596A0 (en) *	2000-12-27	2004-01-04	Salus Pharma Inc	Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US20030133925A1 (en) *	2001-09-28	2003-07-17	Shawar Ribhi M.	Monobactam compositions and methods of use thereof
CA2477979A1 (en) *	2002-03-05	2003-09-18	Transave, Inc.	An inhalation system for treatment of intracellular infections
US7607436B2 (en)	2002-05-06	2009-10-27	The Research Foundation Of State University Of New York	Methods, devices and formulations for targeted endobronchial therapy
WO2004013133A1 (en)	2002-08-05	2004-02-12	TEVA Gyógyszergyár Részvénytársaság	Preparation of aztreonam
WO2004052333A1 (en) *	2002-12-11	2004-06-24	Pari Gmbh	Pharmaceutical compositions for the pulmonary delivery of aztreonam
US20040204439A1 (en) *	2003-04-14	2004-10-14	Staniforth John Nicholas	Composition, device, and method for treating sexual dysfunction via inhalation
AU2004231342A1 (en)	2003-04-14	2004-11-04	Vectura Ltd	Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20060147389A1 (en) *	2004-04-14	2006-07-06	Vectura Ltd.	Devices and pharmaceutical compositions for enhancing dosing efficiency
CN1802371A (zh)	2003-05-15	2006-07-12	特瓦药厂有限公司	残余溶剂含量极低的阿兹托南β多晶型
US7883031B2 (en) *	2003-05-20	2011-02-08	James F. Collins, Jr.	Ophthalmic drug delivery system
AU2004256124B2 (en) *	2003-07-02	2011-04-28	Corus Pharma, Inc.	Aztreonam L-lysine and methods for the preparation thereof
AU2004257632C1 (en) *	2003-07-03	2010-04-15	Gilead Sciences, Inc.	Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2014271333B2 (en) *	2003-07-03	2016-10-27	Gilead Sciences, Inc.	Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) *	2004-01-27	2008-11-18	Gilead Sciences, Inc.	Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) *	2004-03-05	2005-09-22	Pulmatrix, Inc.	Formulations decreasing particle exhalation
GB0425758D0 (en)	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
US20060210483A1 (en) *	2005-03-02	2006-09-21	Kodsi Robert E	Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
JP2008505189A (ja)	2005-05-09	2008-02-21	シコールインコーポレイティド	アズトレオナムの製造方法
US20080107723A1 (en) *	2006-09-28	2008-05-08	Perkins Walter R	Methods of Treating Pulmonary Distress
HUP0700007A2 (en) *	2007-01-08	2008-10-28	Asthma Rehabilitacios Ct Kft	Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
US20110038917A1 (en) *	2007-05-08	2011-02-17	Rq Bioscience, Inc.	Therapeutic compositions and methods for treating gram-negative bacterial infections
GB0714134D0 (en) *	2007-07-19	2007-08-29	Norton Healthcare Ltd	Dry-powder medicament
JP2010540539A (ja) *	2007-10-01	2010-12-24	ギリアードサイエンシーズ，インコーポレイテッド	肺疾患の健康関連クオリティオブライフの欠損を処置するための吸入性アズトレオナムリジン
CA2706637C (en)	2007-11-27	2016-11-29	Algipharma Ipr As	Use of alginate oligomers in combating biofilms
EP2098219A1 (en)	2008-03-05	2009-09-09	PARI Pharma GmbH	Macrolide compositions having improved taste and stability
US20090271021A1 (en) *	2008-04-28	2009-10-29	Popp Shane M	Execution system for the monitoring and execution of insulin manufacture
AU2010229668C1 (en)	2009-03-26	2016-09-15	Pulmatrix Operating Co., Inc.	Dry powder formulations and methods for treating pulmonary diseases
PT2437783E (pt)	2009-06-03	2014-01-22	Algipharma As	Tratamento de acinetobacter com oligómeros de alginato e antibióticos
US10154923B2 (en)	2010-07-15	2018-12-18	Eyenovia, Inc.	Drop generating device
AU2011296343B2 (en)	2010-08-30	2015-12-10	Pulmatrix Operating Company, Inc.	Dry powder formulations and methods for treating pulmonary diseases
US20120076859A1 (en) *	2010-09-23	2012-03-29	Activaero Gmbh	Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
ES2899621T3 (es)	2010-09-29	2022-03-14	Pulmatrix Operating Co Inc	Polvos secos catiónicos que comprenden sal de magnesio
RU2017144619A (ru)	2010-09-29	2019-02-20	Пулмэтрикс, Инк.	Катионы одновалентных металлов сухих порошков для ингаляций
EP2804589A1 (en) *	2012-01-16	2014-11-26	Mahmut Bilgic	Pharmaceutical formulations comprising aztreonam
WO2013130767A1 (en)	2012-02-29	2013-09-06	Pulmatrix, Inc.	Inhalable dry powders
WO2014158201A1 (en) *	2013-03-28	2014-10-02	Pharmacaribe, Llc	Compositions, formulations and methods of bio-balancing the ph of sterile isotonic saline and hypertonic saline solutions
AU2014248455B2 (en)	2013-04-01	2018-12-06	Pulmatrix Operating Company, Inc.	Tiotropium dry powders
CN104784159A (zh) *	2015-04-15	2015-07-22	苏州惠仁生物科技有限公司	氨曲南粉雾剂的制备方法
CN109475707A (zh)	2016-05-03	2019-03-15	精呼吸股份有限公司	用于输送流体到肺部***的液滴输送装置及其使用方法
CN110799231B (zh)	2017-05-19	2022-08-02	精呼吸股份有限公司	干粉输送装置及其使用方法
EP3634550A4 (en)	2017-06-10	2021-03-03	Eyenovia, Inc.	METHODS AND DEVICES FOR HANDLING A FLUID AND DELIVERING THE FLUID TO THE EYE
CN111526914A (zh)	2017-10-04	2020-08-11	精呼吸股份有限公司	电子呼吸致动式直线型液滴输送装置及其使用方法
CA3079189A1 (en)	2017-10-17	2019-04-25	Pneuma Respiratory, Inc.	Nasal drug delivery apparatus and methods of use
CA3082192A1 (en)	2017-11-08	2019-05-16	Pneuma Respiratory, Inc.	Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
CN110898040B (zh) *	2018-09-18	2022-05-17	北京盈科瑞创新药物研究有限公司	一种吸入用氨曲南溶液用冻干粉及其制备方法
CN111647537B (zh) *	2020-06-18	2022-04-26	浙江工业大学	一种耐盐辣椒素降解菌、应用及餐厨垃圾处理方法
EP4359046A1 (en)	2021-06-22	2024-05-01	Pneuma Respiratory, Inc.	Droplet delivery device with push ejection

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US610824A (en) *		1898-09-13		Sleigh attachment for vehicles
US9126A (en) *		1852-07-13		Marcus r
US572801A (en) *		1896-12-08		Telephone-exchange
US673739A (en) *	1900-09-19	1901-05-07	Frank B Stearns	Driving mechanism for vehicles.
US775670A (en) *	1904-08-17	1904-11-22	Thomas F Whittelsey	Air-brake safety device.
US946838A (en) *	1909-08-17	1910-01-18	George Dawson	Tempering compound.
US4775670A (en)	1980-09-29	1988-10-04	E. R. Squibb & Sons, Inc.	2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en)	1980-12-05	1982-06-10	Takeda Chemical Industries Ltd	1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en)	1980-12-05	1987-06-16	Takeda Chemical Industries, Ltd.	4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) *	1981-01-19	1985-07-16	E. R. Squibb & Sons, Inc.	Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4386034A (en) *	1981-02-02	1983-05-31	E. R. Squibb & Sons, Inc.	Sulfamated amino acid amides
US4625022A (en) *	1981-02-02	1986-11-25	E. R. Squibb & Sons, Inc.	Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4572801A (en)	1981-04-30	1986-02-25	Takeda Chemical Industries, Ltd.	4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
CA1181075A (en)	1981-07-13	1985-01-15	David M. Floyd	CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4946838A (en)	1981-07-13	1990-08-07	E. R. Squibb & Sons, Inc.	Crystalline anhydrous aztreonam
US4752469A (en) *	1984-01-09	1988-06-21	E. R. Squibb & Sons, Inc.	Potentiators of beta-lactam antibiotics
US4826973A (en) *	1984-07-20	1989-05-02	E. R. Squibb & Sons, Inc.	Delta form of aztreonam and preparation thereof
US4610824A (en)	1984-10-09	1986-09-09	E. R. Squibb & Sons, Inc.	Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) *	1986-07-11	1989-12-26	Beckman Instruments, Inc.	Sample handling system
CA1339136C (en)	1987-07-01	1997-07-29	Sailesh Amilal Varia	Amorphous form of aztreonam
US5194604A (en) *	1990-06-29	1993-03-16	E. R. Squibb & Sons, Inc.	Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) *	1991-12-12	1998-10-30	Glaxo Group Ltd	Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2105629A1 (en) *	1992-09-14	1994-03-15	Robert S. Becker	Potentiation of immunogenic response
DK0754050T3 (da) *	1994-01-14	2002-10-21	Xoma Technology Ltd	Anti-gram-positive bakterielle fremgangsmåder og materialer
US5508269A (en)	1994-10-19	1996-04-16	Pathogenesis Corporation	Aminoglycoside formulation for aerosolization
US5662929A (en) *	1994-12-23	1997-09-02	Universite De Montreal	Therapeutic liposomal formulation
US5723495A (en)	1995-11-16	1998-03-03	The University Of North Carolina At Chapel Hill	Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) *	1996-04-09	1999-03-02	Vivorx Pharmaceuticals, Inc.	Dry powder inhaler
US6180604B1 (en)	1996-08-21	2001-01-30	Micrologix Biotech Inc.	Compositions and methods for treating infections using analogues of indolicidin
DE69738525T2 (de)	1996-09-04	2009-02-19	Takara Bio Inc., Otsu	Pilz-antigene und verfahren zu deren herstellung
US5994340A (en) *	1997-08-29	1999-11-30	Synphar Laboratories, Inc.	Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en)	1998-06-16	1999-12-16	Serge Dea	Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en)	1998-08-31	2000-03-09	Biogen, Inc.	Method of modulating memory effector t-cells and compositions
EP1161247A4 (en) *	1998-12-17	2002-05-15	Chiron Corp	Treatment method for severe chronic bronchitis (bronchiectasis) using an antibiotic aerosol
WO2000073337A1 (en)	1999-06-01	2000-12-07	Biogen, Inc.	Polymer conjugates of hedgehog proteins and uses
US6576224B1 (en) *	1999-07-06	2003-06-10	Sinuspharma, Inc.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
PT1666028E (pt) *	1999-10-29	2010-06-15	Novartis Ag	Composições de pós anidros com melhor dispersividade
US6962151B1 (en)	1999-11-05	2005-11-08	Pari GmbH Spezialisten für effektive Inhalation	Inhalation nebulizer
DE19953317C1 (de)	1999-11-05	2001-02-01	Pari Gmbh	Inhalationsvernebler
IL156596A0 (en)	2000-12-27	2004-01-04	Salus Pharma Inc	Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) *	2000-12-27	2007-05-08	Corus Pharma, Inc.	Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) *	2000-12-27	2006-11-21	Corus Pharma, Inc.	Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
EP1434685A1 (en) *	2001-10-08	2004-07-07	California Institute Of Technology	Microfabricated lenses, methods of manufacture thereof, and applications therefor
WO2003035030A1 (en)	2001-10-24	2003-05-01	Pari Gmbh	Kit for the preparation of a pharmaceutical composition
CA2477979A1 (en)	2002-03-05	2003-09-18	Transave, Inc.	An inhalation system for treatment of intracellular infections
EP1417958A1 (en)	2002-11-08	2004-05-12	Pari GmbH	Wet granulation process
WO2004052333A1 (en)	2002-12-11	2004-06-24	Pari Gmbh	Pharmaceutical compositions for the pulmonary delivery of aztreonam
AU2004256124B2 (en)	2003-07-02	2011-04-28	Corus Pharma, Inc.	Aztreonam L-lysine and methods for the preparation thereof
JP2010540539A (ja)	2007-10-01	2010-12-24	ギリアードサイエンシーズ，インコーポレイテッド	肺疾患の健康関連クオリティオブライフの欠損を処置するための吸入性アズトレオナムリジン

2001
- 2001-12-20 IL IL15659601A patent/IL156596A0/xx unknown
- 2001-12-20 AU AU2002231244A patent/AU2002231244B2/en active Active
- 2001-12-20 DK DK01991523.0T patent/DK1353647T3/da active
- 2001-12-20 DE DE201112100043 patent/DE122011100043I1/de active Pending
- 2001-12-20 ES ES10010411T patent/ES2406405T3/es not_active Expired - Lifetime
- 2001-12-20 CA CA2433280A patent/CA2433280C/en not_active Expired - Lifetime
- 2001-12-20 DK DK10010411.6T patent/DK2301524T3/da active
- 2001-12-20 BR BRPI0116757A patent/BRPI0116757B8/pt not_active IP Right Cessation
- 2001-12-20 WO PCT/US2001/050062 patent/WO2002051356A2/en active Application Filing
- 2001-12-20 JP JP2002552504A patent/JP4646489B2/ja not_active Expired - Lifetime
- 2001-12-20 EP EP01991523A patent/EP1353647B1/en not_active Expired - Lifetime
- 2001-12-20 PT PT100104116T patent/PT2301524E/pt unknown
- 2001-12-20 EP EP10010411.6A patent/EP2301524B1/en not_active Revoked
- 2001-12-20 US US10/027,113 patent/US6660249B2/en not_active Expired - Lifetime
- 2001-12-20 CA CA2708703A patent/CA2708703C/en not_active Expired - Lifetime
- 2001-12-20 ES ES01991523T patent/ES2360692T3/es not_active Expired - Lifetime
- 2001-12-20 PT PT01991523T patent/PT1353647E/pt unknown
- 2001-12-20 DE DE60144291T patent/DE60144291D1/de not_active Expired - Lifetime
- 2001-12-20 AT AT01991523T patent/ATE502623T1/de active
2003
- 2003-06-23 IL IL156596A patent/IL156596A/en active Protection Beyond IP Right Term
- 2003-06-26 NO NO20032946A patent/NO329643B1/no not_active IP Right Cessation
- 2003-09-04 US US10/654,815 patent/US7208141B2/en not_active Expired - Lifetime
2007
- 2007-03-28 US US11/729,698 patent/US20080050439A1/en not_active Abandoned
2010
- 2010-10-05 NO NO20101377A patent/NO20101377L/no not_active Application Discontinuation
2011
- 2011-01-25 NO NO2011001C patent/NO2011001I2/no unknown
- 2011-06-16 CY CY20111100581T patent/CY1111571T1/el unknown
- 2011-08-03 LU LU91851C patent/LU91851I2/fr unknown
- 2011-08-05 NL NL300492C patent/NL300492I2/nl unknown
- 2011-08-16 FR FR11C0030C patent/FR11C0030I2/fr active Active
- 2011-08-22 CY CY2011012C patent/CY2011012I2/el unknown
- 2011-09-08 BE BE2011C029C patent/BE2011C029I2/fr unknown
- 2011-12-19 US US13/330,633 patent/US20120093890A1/en not_active Abandoned
2012
- 2012-07-19 IL IL221036A patent/IL221036A0/en unknown
2013
- 2013-10-04 US US14/046,539 patent/US9533000B2/en not_active Expired - Lifetime
2016
- 2016-11-15 US US15/352,364 patent/US20170296517A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2708703C (en)	2012-12-04
NL300492I2 (nl)	2017-11-02
EP1353647A2 (en)	2003-10-22
BE2011C029I2 (no)	2021-07-26
EP1353647B1 (en)	2011-03-23
NO20101377L (no)	2003-08-26
US20030055034A1 (en)	2003-03-20
US20080050439A1 (en)	2008-02-28
US6660249B2 (en)	2003-12-09
ES2406405T3 (es)	2013-06-06
WO2002051356A2 (en)	2002-07-04
DE122011100043I1 (de)	2011-12-15
WO2002051356A3 (en)	2002-10-31
DK2301524T3 (da)	2013-07-15
ATE502623T1 (de)	2011-04-15
LU91851I2 (fr)	2011-10-03
NO2011001I2 (no)	2013-05-27
NO2011001I1 (no)	2011-02-07
AU2002231244B2 (en)	2006-06-29
JP4646489B2 (ja)	2011-03-09
IL156596A0 (en)	2004-01-04
US20140037735A1 (en)	2014-02-06
DE60144291D1 (de)	2011-05-05
IL156596A (en)	2012-07-31
CA2708703A1 (en)	2002-07-04
CY1111571T1 (el)	2014-04-09
BR0116757B1 (pt)	2014-02-04
BR0116757A (pt)	2003-11-04
US20050129623A1 (en)	2005-06-16
FR11C0030I2 (fr)	2012-03-16
FR11C0030I1 (no)	2011-09-23
US20120093890A1 (en)	2012-04-19
IL221036A0 (en)	2012-08-30
DK1353647T3 (da)	2011-06-14
US9533000B2 (en)	2017-01-03
US20170296517A1 (en)	2017-10-19
EP1353647A4 (en)	2007-05-09
NO329643B1 (no)	2010-11-22
CA2433280C (en)	2010-09-21
CY2011012I1 (el)	2014-04-09
JP2004516302A (ja)	2004-06-03
NO20032946L (no)	2003-08-26
CA2433280A1 (en)	2002-07-04
PT1353647E (pt)	2011-05-24
PT2301524E (pt)	2013-07-10
US7208141B2 (en)	2007-04-24
EP2301524A1 (en)	2011-03-30
BRPI0116757B8 (pt)	2021-05-25
CY2011012I2 (el)	2014-04-09
ES2360692T3 (es)	2011-06-08
LU91851I9 (no)	2019-01-03
EP2301524B1 (en)	2013-04-24

Legal Events

Date

Code

Title

Description

2011-02-07

SPCF

Filing of supplementary protection certificate

Free format text: PRODUCT NAME: CAYSTON; NAT. REG. NO/DATE: EU71/09/543/001/NO 20091015; FIRST REG. NO/DATE: EU/1/09/543/001 20090921

Spc suppl protection certif: 2011001

Filing date: 20110125

2013-05-27

SPCG

Granted supplementary protection certificate